Lung India · 2018 · 10 citations · 11 references
MedicineOncologyPharmacologyMolecular OncologyNeoplasiaTumor ProgressionCancer ProgressionLung CancerMalignant NeoplasmsTargeted Cancer TherapyTumor BiologyTyrosine Kinase InhibitorsEgfr InhibitionEpidermal Growth Factor Receptor InhibitionLung AdenocarcinomaMolecular Drug ResistanceNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentOncogenic Receptor Tyrosine Kinase MutationsTherapeutic Tyrosine Kinase Inhibitors
A subset of non-small cell lung carcinoma (NSCC) harbor active mutations of epidermal growth factor receptor (EGFR). In these, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are recommended as the first-line treatment. Though drug resistance is inevitable, histological transformation to small cell lung carcinoma (SCLC) is a rare mechanism for acquired resistance. Here we report one such rare case of histological transformation of pulmonary adenocarcinoma to small cell lung carcinoma in 46 year old male treated with Gefitinib.
11